-
Biotech Company Opthea Aims To Raise $160M In US IPO
Monday, October 12, 2020 - 1:10am | 305Read More...Opthea Limited, a biotechnology company focussed on retinal diseases, announced Sunday it is seeking an initial public offering in the United States. What Happened: The Melbourne Australia-based biopharmaceutical company will offer American Depositary Shares each of which will represent eight of...
-
Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval
Friday, January 24, 2020 - 6:52am | 313Read More...Biopharmaceutical company Epizyme Inc. (NASDAQ: EPZM) on Thursday said that its tazemetostat drug for the treatment of patients with epithelioid sarcoma had been approved by the Food and Drug Administration. What Happened The TAZVERIK drug has been approved, particularly for the...
-
Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation
Wednesday, September 19, 2018 - 3:43pm | 461Read More...Clinical-stage biopharma Surface Oncology, Inc. (NASDAQ: SURF) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research. The Analyst Analyst Michael Ulz initiated coverage of...
-
A Survey Of Celgene's M&A Strategy
Friday, January 19, 2018 - 10:41am | 1550Read More...M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG) is pursuing Juno Therapeutics Inc (NASDAQ: JUNO). The report triggered a massive 52-percent upward move in shares of...
-
After A Freefall In Axovant Shares, Chardan Upgrades
Wednesday, January 10, 2018 - 12:45pm | 390Read More...Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial. The Analyst...
-
Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making
Wednesday, January 10, 2018 - 11:26am | 449Read More...Clinical-stage biopharma company Epizyme Inc (NASDAQ: EPZM)'s tazemetostat has shown effectiveness in treating blood cancers and solid tumors with minimal toxicities in early- and mid-stage trials, according to Morgan Stanley. Tazemetostat is an EZH2 inhibitor that moderates gene...
-
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More
Wednesday, December 13, 2017 - 1:31pm | 1362Read More...The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...
-
11 Biotech Stocks Moving From ASH 2017
Monday, December 11, 2017 - 5:24pm | 1170Read More...The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...
-
Piper Jaffray: Akorn's Stock Will Be Delisted In 2016
Friday, December 18, 2015 - 12:18pm | 441Read More...Shares of Akorn, Inc. (NASDAQ: AKRX) are lower by nearly 3 percent since the start of 2015. Despite the stock's $4 billion-plus valuation, Joshua Schimmer of Piper Jaffray suggested that it is "hard to rule out a delisting." The analyst cited uncertainty over the company...
-
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Friday, December 18, 2015 - 11:52am | 1283Read More...Joshua Schimmer of Piper Jaffray commented in a note that he is "eager to hit the reset button" within the biopharma sector. Schimmer presented a list of potential outcomes and events in 2016 which represent contrarian views or ones that investors "aren't even...
-
What Should Biotech Investors Do Now?
Tuesday, August 25, 2015 - 2:47pm | 472Read More...Benzinga recently had the chance to talk with Jason Napodano, biopharma analyst and consultant, and owner of BioNap Consulting. Below is a look at some highlights from the expert. Macro Conditions And The Biotech Industry When asked about the current state of macro conditions for the biotech...
